{
    "organizations": [],
    "uuid": "3984eeb1f823a22c82ec82a7fa3db6072d46a37a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-acelrx-announces-fda-acceptance-of/brief-acelrx-announces-fda-acceptance-of-nda-for-dsuvia-idUSASC0A3J3",
    "ord_in_thread": 0,
    "title": "BRIEF-AcelRx Announces FDA Acceptance Of NDA For Dsuvia",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 24 (Reuters) - AcelRx Pharmaceuticals Inc:\n* ACELRX PHARMACEUTICALS INC - DSUVIA PDUFA DATE SET FOR NOVEMBER 3, 2018\n* ACELRX ANNOUNCES FDA ACCEPTANCE OF NDA FOR DSUVIA * ACELRX PHARMACEUTICALS INC - FDA CONSIDERS DSUVIA NDA RESUBMISSION A COMPLETE CLASS 2 RESPONSE TO THEIR OCTOBER 2017 ACTION LETTER Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-24T19:14:00.000+03:00",
    "crawled": "2018-05-25T16:22:41.007+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "acelrx",
        "pharmaceutical",
        "inc",
        "acelrx",
        "pharmaceutical",
        "inc",
        "dsuvia",
        "pdufa",
        "date",
        "set",
        "november",
        "acelrx",
        "announces",
        "fda",
        "acceptance",
        "nda",
        "dsuvia",
        "acelrx",
        "pharmaceutical",
        "inc",
        "fda",
        "considers",
        "dsuvia",
        "nda",
        "resubmission",
        "complete",
        "class",
        "response",
        "october",
        "action",
        "letter",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}